



CD73⁺ adipose-derived stem cells reduce scar formation through PLOD1

Miao Xu¹, Shuo Fang², Xiaorong Ma¹

¹Department of Plastic and Reconstructive Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;

²Department of Plastic and Reconstructive Surgery, Changhai Hospital, Naval Medical University, Shanghai, China

Contributions: (I) Conception and design: M Xu, X Ma; (II) Administrative support: M Xu, X Ma; (III) Provision of study materials or patients: M Xu, X Ma; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Xiaorong Ma. Department of Plastic and Reconstructive Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai 200092, China. Email: maxiaorong@xinhumed.com.cn.

Background: Reducing cutaneous scar formation is important for assessing the success of skin wound healing. Although it is generally accepted that adipose-derived mesenchymal stem cells (AMSCs) have substantial therapeutic potential, efforts are continuously made to improve the outcome of AMSC therapy. Post-transcriptional suppression of procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 (PLOD1) in AMSCs has been shown to greatly reduce scar formation during skin wound healing, likely through modulating macrophage polarization. In the present study, we tested whether a CD73⁺ subpopulation of AMSCs could reduce scar formation compared with CD73⁻ AMSCs.

Methods: The gene profile of CD73⁺ versus CD73⁻ AMSCs was obtained from a validated public database, GSE167219. AMSCs were isolated from adipose tissue surrounding the groin of mice, after which CD73⁺ versus CD73⁻ AMSCs were sorted using flow cytometry. PLOD1 levels were determined in CD73⁺ versus CD73⁻ AMSCs. Then, PLOD1 in CD73⁻ AMSCs was depleted by a short-hair interfering RNA against PLOD1 (sh-PLOD1), while PLOD1 in CD73⁺ AMSCs was increased by expression of a PLOD1 transgene. A blade was used to induce a skin injury on the middle back of the mice. Either CD73⁺ AMSCs or CD73⁻ PLOD1 AMSCs or CD73⁻ AMSCs or CD73⁻ sh-PLOD1 AMSCs were intravenously transplanted into the injured region of the mice. Fibrosis and the underlying mechanisms were investigated. Co-immunoprecipitation was performed to evaluate interaction between CD73 and PLOD1.

Results: CD73⁺ AMSCs expressed significantly lower levels of PLOD1, a potent stimulator of fibrosis, compared with CD73⁻ AMSCs. Transplantation of CD73⁺ AMSCs generated significantly reduced fibrosis at the skin injury site compared with CD73⁻ AMSCs. However, expression of PLOD1 in CD73⁺ AMSCs abolished its advantageous effects on fibrosis reduction, while depletion of PLOD1 in CD73⁻ AMSCs improved the outcome of fibrosis to the levels of transplantation of CD73⁺ AMSCs. Co-immunoprecipitation showed no direct protein interaction between CD73 and PLOD1.

Conclusions: CD73⁺ AMSCs are a subgroup of AMSCs with better therapeutic effects on wound healing, and can inhibit scar formation through reduced PLOD1 in an indirect manner.

Keywords: Scar formation; adipose-derived mesenchymal stem cells (AMSCs); CD73; procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 (PLOD1)

Submitted Nov 22, 2021. Accepted for publication Dec 23, 2021.

doi: 10.21037/atm-21-6557

View this article at: <https://dx.doi.org/10.21037/atm-21-6557>

Introduction

Damaged cutaneous tissue can be replaced with an abnormal connective tissue during tissue regeneration to generate a specific structure known as a scar (1). The formation of scar impairs the regulator functionality of the normal skin, resulting in reduction in tensile and dysfunction (2). Anti-inflammatory therapy with IL-10 or tumor necrosis factor alpha stimulated gene 6, or anti-angiogenesis therapy with anti-vascular endothelial growth factor monoclonal antibody may help to inhibit scar formation.

Stem cell transplantation has been shown to be an effective treatment during wound healing (3), in which scar formation is substantially reduced. Mesenchymal stem cells (MSCs), especially adipose-derived MSCs (AMSCs), are most used due to their relative safety, easy access, and rich abundance (4-7). We recently showed that transcriptional regulation of procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 (PLOD1) expression in AMSCs can further improve the therapeutic outcome of AMSCs. PLOD1 has been shown to be crucial for lysine residue hydroxylation in collagen telopeptides and for the collagen pyridinoline to develop fibrotic cross-links (8). Previous studies have demonstrated a beneficial effect of PLOD1 suppression on skin regeneration with reduced scar formation (9-14). However, to the best of our knowledge, our study is the first to show that the therapeutic potential of AMSCs can be improved by modulation of PLOD1 levels.

CD73, encoded by the *NT5E* gene in humans, is an enzyme that mediates conversion of adenosine monophosphate to adenosine (15). Recent studies have shown that CD73 can be used as a marker to separate AMSCs into the following two subgroups: CD73⁺ AMSCs and CD73⁻ AMSCs. CD73⁺ AMSCs demonstrate better effects during cardiac muscular regeneration and during recovery from spinal cord injury (16,17). However, whether CD73⁺ AMSCs are more beneficial than total AMSCs or CD73⁻ AMSCs in skin wound repair, as well as the role of PLOD1 in CD73⁺ AMSCs in terms of regenerative potential, is not known, and therefore, addressed in this study.

We present the following article in accordance with the ARRIVE reporting checklist (available at <https://atm.amegroups.com/article/view/10.21037/atm-21-6557/rc>).

Methods

Protocols and animals

The present study received approval from the Research and Animal Ethics Association of Shanghai Jiao Tong University (No. XHEC-F-2021-071) in compliance with Shanghai Jiao Tong University institutional guidelines for the care and use of animals. A protocol was prepared before the study without registration. Both male and female 12-week-old C57BL/6 mice (about 25 and 20 g, respectively) were used in the present study, and were both purchased from Shanghai Laboratory Animals Center Laboratory Animal Co., Ltd. (Shanghai, China). Mice of different sexes were distributed evenly into each experimental group. A 12-h light-dark cycle was applied to mouse housing. The mouse number in each experimental group was determined by power calculations ($P < 0.05$) to guarantee the legitimacy of the results. An allocation concealment method was applied to reduce confounders. No criteria were used for excluding animals during the experiment. No data were excluded during the analysis. No humane endpoints were involved in the current study. Skin injury was induced as previously described. For the *in vivo* experiment, the mice were allocated to the following 9 groups: group 1, mice were sham treated; group 2, mice received skin injury and transplantation of saline; group 3, mice received skin injury and transplantation of AMSCs; group 4, mice received skin injury and transplantation of CD73⁻ AMSCs; group 5, mice received skin injury and transplantation of CD73⁻ AMSCs transfected with scrambled (scr) plasmid; group 6, mice received skin injury and transplantation of CD73⁻ AMSCs transfected with siRNA for PLOD1 (siPLOD1) plasmid; group 7, mice received skin injury and transplantation of CD73⁺ AMSCs; group 8, mice received skin injury and transplantation of CD73⁺ AMSCs transfected with scr; and group 9, mice received skin injury and transplantation of CD73⁺ AMSCs transfected with PLOD1 plasmid.

Isolation and sorting for CD73⁻ versus CD73⁺ AMSCs

AMSCs were isolated from 12-week-old C57BL/6 mice, as previously described. AMSCs were cultured in Dulbecco's modified Eagle medium supplemented with 15% fetal bovine serum. For separation of CD73⁻ versus CD73⁺

AMSCs, a PE-cy7-conjugated rabbit anti-mouse CD73 antibody was used for flow cytometry-based cell sorting. Data were analyzed using FlowJo software (FlowJo LLC., Ashland, OR, USA).

Transfection of AMSCs

Transfection of AMSCs was done with Lipofectamine 3000 reagent (Invitrogen, St Louis, MO, USA) using plasmids carrying complete coding sequence for PLOD1, or a siRNA for PLOD1 (siPLOD1), or a scr as a control, all under control of a cytomegalovirus (CMV) promoter. The construct also contained a green fluorescent protein reporter (connected with a 2A sequence) with the transgene to allow evaluation of the transfection efficiency (about 90% in total).

Transplantation of different AMSCs

A total of 2×10^6 differently modified AMSCs were prepared in 150 μ L normal saline and then injected into the tail vein of the mice 3 days before injury formation, as the transplanted cells need time for homing.

Histology

Masson trichrome staining was performed using trichrome Stain (Masson) kit (Sigma-Aldrich, St. Louis, MO, USA).

Enzyme-linked immunosorbent assay (ELISA)

Protein levels for PLOD1 and CD73 were detected by anti-PLOD1 or anti-CD73 ELISA kits (R&D, Carpinteria, CA, USA), respectively.

Quantitative polymerase chain reaction

Total RNA extraction was done using an RNeasy kit (Qiagen, Hilden, Germany), and quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed with a QuantiTect SYBR Green PCR kit (Qiagen, Shanghai, China). Commercial primers were all purchased from Qiagen. An $2^{-\Delta\Delta C_t}$ method was used for analysis of gene transcript levels. Relative gene expression was determined by sequential normalization of the values against internal and experimental controls.

Bioinformatics and statistical analysis

A bioinformatics analysis on the differential gene profiles of CD73⁻ versus CD73⁺ AMSCs was done using a validated public dataset, GSE167219. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Data quality was carefully confirmed using mean difference plot, mean variance trend plot, *t*-statistic quantile-quantile plot, and boxplot to ensure that all of the included data were reliable. All statistical analyses (one-way analysis of variance with a Bonferroni correction) were conducted by GraphPad Prism software (version 7; GraphPad Software, La Jolla, CA, USA). Data were represented as mean \pm standard deviation and the significance was set at $P < 0.05$.

Results

Validation of a gene profile data for CD73⁻ versus CD73⁺ AMSCs

Recent studies have shown that CD73 can be used as a marker to separate AMSCs into the following two subgroups: CD73⁺ AMSCs and CD73⁻ AMSCs. CD73⁺ AMSCs demonstrate better effects during cardiac muscular regeneration and during recovery from spinal cord injury (16,17). However, whether CD73⁺ AMSCs are more beneficial than total AMSCs or CD73⁻ AMSCs in skin wound repair, as well as the role of PLOD1 in the CD73⁺ AMSCs in terms of regenerative potential, is not known. Therefore, we first examined public databases to address these questions.

A public dataset (GSE167219) was validated by boxplot analysis (*Figure 1A*), mean variance trend plot (*Figure 1B*), *t*-statistic quantile-quantile plot (*Figure 1C*), and principal component analysis (PCA) plot (*Figure 1D*) to ensure that the data in this database were reliable and for analysis.

PLOD1 levels are significantly higher in CD73⁻ AMSCs versus CD73⁺ AMSCs

We then examined the differential genes between CD73⁻ AMSCs and CD73⁺ AMSCs. The results are shown in volcano maps (*Figure 2A,2B*). We found that PLOD1 levels are significantly higher in CD73⁻ AMSCs versus CD73⁺ AMSCs (*Figure 2B*). To further confirm it, we separated CD73⁻ AMSCs versus CD73⁺ AMSCs by flow cytometry




Figure 1 Validation of a gene profile data for CD73⁻ versus CD73⁺ adipose-derived mesenchymal stem cells. (A-D) GSE167219 public dataset was validated by boxplot analysis (A), mean variance trend plot (B), *t*-statistic quantile-quantile plot (C), and principal component analysis plot (D), and ensured that the data in this database were reliable for analysis.

(Figure 2C). The isolated CD73⁻ AMSCs and CD73⁺ AMSCs did not show big difference in morphology in culture (Figure 2D). qRT-PCR for CD73 was performed on CD73⁻ AMSCs versus CD73⁺ AMSCs, which confirmed the proper separation of populations based on CD73 levels. PLOD1 levels in CD73⁺ AMSCs were lower than those CD73⁻ AMSCs by more than 80% (Figure 2E).

Preparation of plasmids to modify PLOD1 levels in CD73⁻ AMSCs and CD73⁺ AMSCs

After detecting significantly lower PLOD1 in CD73⁺ AMSCs versus CD73⁻ AMSCs, and demonstrating the beneficial effect of AMSCs by PLOD1 depletion, we hypothesized that CD73⁺ AMSCs might have a better effect on wound repair and generate reduced scar formation compared with total AMSCs or CD73⁻ AMSCs. To prove this, we first generated plasmids to modify PLOD1 levels through expressing PLOD1 or siPLOD1. Plasmids carrying

a scr sequence were used as a control (Figure 3A). We first confirmed the CD73 mRNA levels (Figure 3B) and CD73 protein levels (Figure 3C) in CD73⁺ AMSCs versus CD73⁻ AMSCs by qRT-PCR and ELISA, respectively. Neither the expression of PLOD1 nor siPLOD1 altered levels of CD73 (Figure 3B, 3C). Moreover, siPLOD1 significantly decreased PLOD1 mRNA levels (Figure 3B) and PLOD1 protein levels (Figure 3C) in CD73⁻ AMSCs, while PLOD1 significantly increased PLOD1 mRNA levels (Figure 3B) and PLOD1 protein levels (Figure 3C) in CD73⁺ AMSCs.

Transplantation of CD73⁺ AMSCs further reduces fibrosis after skin injury in mice compared with transplantation of total or CD73⁻ AMSCs

The *in vivo* effects of the specific AMSC subpopulations on post-injury fibrosis on mouse skin were then analyzed. The mice were assigned to the following nine groups: group 1, mice were sham treated; group 2, mice received




Figure 2 PLOD1 levels are significantly higher in CD73⁻ AMSCs versus CD73⁺ AMSCs. (A,B) We examined differential genes between CD73⁻ AMSCs and CD73⁺ AMSCs. Results are shown in volcano maps in A and B. We found that PLOD1 levels are significantly higher in CD73⁻ AMSCs versus CD73⁺ AMSCs; (C) we separated CD73⁻ AMSCs versus CD73⁺ AMSCs by flow cytometry, shown by a representative flow chart; (D) isolated CD73⁻ AMSCs and CD73⁺ AMSCs in culture; (E) quantitative reverse transcription polymerase chain reaction for CD73 and PLOD1 on CD73⁻ AMSCs versus CD73⁺ AMSCs. *, $P < 0.05$. $n = 5$. Scale bars are 100 μm . PLOD1, procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1; AMSCs, adipose-derived mesenchymal stem cells; FSC, forward scatter.

skin injury and transplantation of saline; group 3, mice received skin injury and transplantation of AMSCs; group 4, mice received skin injury and transplantation of CD73⁻ AMSCs; group 5, mice received skin injury and transplantation of CD73⁻ AMSCs transfected with scr plasmid; group 6, mice received skin injury and

transplantation of CD73⁻ AMSCs transfected with siPLOD1 plasmid; group 7, mice received skin injury and transplantation of CD73⁺ AMSCs; group 8, mice received skin injury and transplantation of CD73⁺ AMSCs transfected with scr plasmid; and group 9, mice received skin injury and transplantation of CD73⁺ AMSCs




Figure 3 Preparation of plasmids to modify PLOD1 levels in CD73⁻ AMSCs and CD73⁺ AMSCs. (A) Generation of plasmids to modify PLOD1 levels through expression of PLOD1 or siRNA for PLOD1 (siPLOD1). Plasmids carrying a scrambled sequence were used as controls; (B,C) levels of CD73 and PLOD1 were determined in transfected cells by quantitative reverse transcription polymerase chain reaction (B), and by enzyme-linked immunosorbent assay (C). *, $P < 0.05$. $n = 5$. NS, no significance; PLOD1, procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1; AMSCs, adipose-derived mesenchymal stem cells; GFP, green fluorescent protein.

transfected with PLOD1 plasmid. We evaluated the effects on fibrosis 2 weeks after skin injury. Through quantitative analysis on fibrotic tissue by Masson staining, we found that transplantation of CD73⁺ AMSCs resulted in less fibrosis on injured mouse skin compared with transplantation of total AMSCs, while transplantation of CD73⁻ AMSCs resulted in more fibrosis on injured mouse skin compared with transplantation of total AMSCs (Figure 4A,4B), suggesting that CD73⁺ AMSCs could have a better therapeutic potential.

Better therapeutic effects of CD73⁺ AMSCs on skin wound repair could result from reduced PLOD1 expression

Next, we found that PLOD1 depletion completely abolished

increased fibrosis by CD73⁻ AMSC transplantation, while no difference was detected between transplantation of CD73⁻ AMSCs and transplantation of CD73⁻ AMSCs transfected with scr (Figure 4A,4B). Moreover, PLOD1 expression completely abolished reduced fibrosis by CD73⁺ AMSC transplantation, while no difference was detected between transplantation of CD73⁺ AMSCs and transplantation of CD73⁺ AMSCs transfected with scr (Figure 4A,4B). Together, these data suggest that better therapeutic effects of CD73⁺ AMSCs on skin wound repair could result from reduced PLOD1 expression.

CD73 does not directly interact with PLOD1

Finally, we examined whether CD73 might directly interact




Figure 4 Better therapeutic effects of CD73⁺ AMSCs on skin wound repair could result from reduced PLOD1 expression. *In vivo* effects by these modifications on post-injury fibrosis on mouse skin were assessed. Mice were assigned to the following 9 groups. Fibrosis was determined by Masson staining 2 weeks after skin injury, as shown in the representative images (A) and by quantification (B). *, $P < 0.05$. $n = 10$. Scale bars are 100 μm . AMSCs, adipose-derived mesenchymal stem cells; PLOD1, procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1; NS, no significance.

with PLOD1. Co-immunoprecipitation for CD73 and PLOD1 was then performed, showing no direct interaction between them (Figure 5). Therefore, CD73 could regulate PLOD1 indirectly.

Discussion

It is very important to generate a more effective stem cell-based therapeutic approach to boost skin wound repair and to determine the underlying cellular and molecular




Figure 5 CD73 does not directly interact with PLOD1. Co-immunoprecipitation for CD73 and PLOD1 was therefore performed, showing no direct interaction between them. PLOD1, procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1; -, not overexpressed in cells; +, overexpressed in cells.

mechanisms (5-7). PLOD1 appeared to be a rising star at the center of the studies, and our recent studies specifically used PLOD1 as a potential target.

Recently, we showed that PLOD1 can be post-transcriptionally suppressed in AMSCs, which improves the outcome of AMSC transplantation for skin wound repair. Differential ability of AMSC has a limitation. However, in the present study, we further showed that CD73⁺ AMSCs have better therapeutic potential compared with total AMSCs, likely due to the low expression of PLOD1. It is noteworthy that previous studies have demonstrated that CD73⁺ AMSCs are more like stem cells and have a regulatory effect on inflammation, perhaps through recruitment and polarization of macrophages (16). We have previously shown that the profibrotic effect of PLOD1 could result from its regulation of macrophage polarization. Therefore, the effects of CD73⁺ AMSCs on macrophages could at least partially result from their low expression of PLOD1.

The cross-talk between PLOD1 and CD73 is unknown. Several online protein interaction tools have been examined; none showed a direct binding relationship between the two proteins. Our data also showed no evidence of direct interaction between PLOD1 and CD73; therefore, their regulatory relationship should be indirect and could involve multiple signaling pathways.

In the present study, we did not analyze the recruitment, proliferation, and polarization of macrophages by CD73⁺ AMSCs compared with total AMSCs and CD73⁻ AMSCs. These should be investigated in future studies, as

macrophages are likely important targets for both CD73 and PLOD1. It might also be interesting to compare the wound healing effect of CD73⁺ AMSCs and adipose stem cells exosomes. Other potential mechanisms of CD73⁺ AMSCs to inhibit scar formation may involve decreases in nitric oxide, p53 and TGFβ activity to inhibit fibroblast proliferation.

In conclusion, the current study, we provided robust evidence for using CD73⁺ AMSCs as a novel therapeutic approach to boost skin wound repair with attenuated scar formation.

Acknowledgments

Funding: This work was supported by the National Natural Science Foundation of China (grant No. 81701949).

Footnote

Reporting Checklist: The authors have completed the ARRIVE reporting checklist. Available at <https://atm.amegroupp.com/article/view/10.21037/atm-21-6557/rc>

Data Sharing Statement: Available at <https://atm.amegroupp.com/article/view/10.21037/atm-21-6557/dss>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroupp.com/article/view/10.21037/atm-21-6557/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The present study was approved by the Research and Animal Ethics Association of Shanghai Jiao Tong University (No. XHEC-F-2021-071) in accordance with Shanghai Jiao Tong University institutional guidelines for the care and use of animals. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the

original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Visscher MO, Bailey JK, Hom DB. Scar treatment variations by skin type. *Facial Plast Surg Clin North Am* 2014;22:453-62.
2. Rhett JM, Ghatnekar GS, Palatinus JA, et al. Novel therapies for scar reduction and regenerative healing of skin wounds. *Trends Biotechnol* 2008;26:173-80.
3. Li Q, Zhang C, Fu X. Will stem cells bring hope to pathological skin scar treatment? *Cytotherapy* 2016;18:943-56.
4. Jackson WM, Nesti LJ, Tuan RS. Mesenchymal stem cell therapy for attenuation of scar formation during wound healing. *Stem Cell Res Ther* 2012;3:20.
5. Wang Y, Chu Y, Yue B, et al. Adipose-derived mesenchymal stem cells promote osteosarcoma proliferation and metastasis by activating the STAT3 pathway. *Oncotarget* 2017;8:23803-16.
6. Chen KH, Chen CH, Wallace CG, et al. Intravenous administration of xenogenic adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes markedly reduced brain infarct volume and preserved neurological function in rat after acute ischemic stroke. *Oncotarget* 2016;7:74537-56.
7. Zhong Z, Gu H, Peng J, et al. GDNF secreted from adipose-derived stem cells stimulates VEGF-independent angiogenesis. *Oncotarget* 2016;7:36829-41.
8. Anum EA, Hill LD, Pandya A, et al. Connective tissue and related disorders and preterm birth: clues to genes contributing to prematurity. *Placenta* 2009;30:207-15.
9. Knipper JA, Willenborg S, Brinckmann J, et al. Interleukin-4 Receptor α Signaling in Myeloid Cells Controls Collagen Fibril Assembly in Skin Repair. *Immunity* 2015;43:803-16.
10. van den Bogaerdt AJ, van der Veen VC, van Zuijlen PP, et al. Collagen cross-linking by adipose-derived mesenchymal stromal cells and scar-derived mesenchymal cells: Are mesenchymal stromal cells involved in scar formation? *Wound Repair Regen* 2009;17:548-58.
11. Ulrich MM, Verkerk M, Reijnen L, et al. Expression profile of proteins involved in scar formation in the healing process of full-thickness excisional wounds in the porcine model. *Wound Repair Regen* 2007;15:482-90.
12. van der Slot AJ, Zuurmond AM, van den Bogaerdt AJ, et al. Increased formation of pyridinoline cross-links due to higher telopeptide lysyl hydroxylase levels is a general fibrotic phenomenon. *Matrix Biol* 2004;23:251-7.
13. Bank RA, Robins SP, Wijmenga C, et al. Defective collagen crosslinking in bone, but not in ligament or cartilage, in Bruck syndrome: indications for a bone-specific telopeptide lysyl hydroxylase on chromosome 17. *Proc Natl Acad Sci U S A* 1999;96:1054-8.
14. Yamada H, Tajima S, Nishikawa T, et al. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. *J Biochem* 1994;116:892-7.
15. Alcedo KP, Bowser JL, Snider NT. The elegant complexity of mammalian ecto-5'-nucleotidase (CD73). *Trends Cell Biol* 2021;31:829-42.
16. Li Q, Hou H, Li M, et al. CD73+ Mesenchymal Stem Cells Ameliorate Myocardial Infarction by Promoting Angiogenesis. *Front Cell Dev Biol* 2021;9:637239.
17. Zhai X, Chen K, Yang H, et al. Extracellular vesicles derived from CD73 modified human umbilical cord mesenchymal stem cells ameliorate inflammation after spinal cord injury. *J Nanobiotechnology* 2021;19:274.

(English Language Editor: R. Scott)

Cite this article as: Xu M, Fang S, Ma X. CD73⁺ adipose-derived stem cells reduce scar formation through PLOD1. *Ann Transl Med* 2022;10(2):66. doi: 10.21037/atm-21-6557